This paper summarizes P2X7 antagonist trials to treat ALS animal model. The manuscript contains interesting entities and worth publishing in Neurodegenerative Disease and Neural Regeneration if the following questions were properly answered. It is difficult to understand P2X7 antagonist BBG still has some effect to P2X7 knockout (P2X7KO)/SOD1 G93A mice which was mentioned in the 4th paragraph. Authors also expressed their concerns about specificity and BBB permeability of BBG in 7th and 8th paragraph, respectively. In these consequences, the whole discussion is not convincing. Background stories on discovery of BBG would partly help us to understand. Brief explanation on animal model of ALS overexpressing SOD1G93A will also be valuable for readers.
